ライフサイエンスコーパス: beta-chemokine

1 ific production of both interferon-gamma and beta-chemokine.

2 The soluble factor involved was not a beta-chemokine.

3 ate that Exodus represents a novel divergent beta-chemokine.

4 the previously described HIV R5-suppressive beta chemokines.

5 d protein, designated MCK-1, has homology to beta chemokines.

6 tion of HIV-1-suppressive factors, including beta chemokines.

7 rated an increased migratory response to the beta chemokines.

8 laboration of interferon-gamma and antiviral beta chemokines.

9 microglia and astrocytes produced all three beta chemokines.

10 rved cysteine residues typical for mammalian beta chemokines.

11 easured by expression of TNF-alpha and three beta chemokines.

12 state levels of mRNA specific for these two beta-chemokines.

13 nsensitive to the antiviral effects of these beta-chemokines.

14 nd resistance was abrogated by antibodies to beta-chemokines.

15 ell surface and with increased production of beta-chemokines.

16 ial tumor Kaposi's sarcoma, encodes three CC/beta-chemokines.

17 ned media produced significant quantities of beta-chemokines.

18 CCR5 expression and increasing production of beta-chemokines.

19 addition to the four others conserved in all beta-chemokines.

20 s caused rapid and specific release of these beta-chemokines.

21 inactive in signal transduction mediated by beta-chemokines.

22 ever, had NSI viruses that were sensitive to beta-chemokines.

23 NSI HIV-1 strains and secrete high levels of beta-chemokines.

24 the presence of CD8+ T-cell supernatants or beta-chemokines.

25 T cells cannot be explained entirely by the beta-chemokines.

26 cycle in late G(1), contained high levels of beta-chemokines.

27 ed by changes in the levels of CD4, CCR5, or beta-chemokines.

28 activity of CAF that is not attributable to beta-chemokines.

29 normal individuals that synthesize antiviral beta-chemokines.

30 ecretion of gamma interferon (IFN-gamma) and beta-chemokines.

31 CD8+ lymphocytes are a major source of beta-chemokines [3], but the stimulus for chemokine rele

32 Alignment of beta-chemokine amino acid sequences revealed the presenc

33 Although AOP-RANTES and other beta-chemokine analogs are potent inhibitors, the extrem

34 The beta chemokines and antibodies to CCR3 failed to affect

35 CCR5 is a receptor for several beta chemokines and the entry coreceptor used by macroph

36 gH contributes to this process by modulating beta-chemokine and interleukin 6 (Il6) expression.

37 of African green monkeys (AGMs) avidly binds beta-chemokines and functions as a coreceptor for simian

38 shows a differential effect on production of beta-chemokines and gamma interferon.

39 orphine on gene expression of the alpha- and beta-chemokines and their receptors by the astrocytoma c

40 beta-Chemokines and their receptors mediate the traffick

41 endogenous suppressive factors, such as the beta-chemokines, and HIV-inducing cytokines, such as tum

42 Here, we show that all three beta-chemokines, and MIP-1alpha in particular, inhibit p

43 ugh endogenously produced factors, including beta-chemokines, and that beta-chemokine production by C

44 on, the frequency of CD8+ T cells expressing beta-chemokines, and the extent of CD8+-T-cell prolifera

45 be partially reversed by treatment with anti-beta-chemokine antibodies.

46 n found in the macrophage-rich lesions where beta-chemokines are being produced.

47 Beta-chemokines are expressed by tubular epithelial cell

48 These observations indicate that beta-chemokines are responsible for a major proportion o

49 The findings indicate that alpha and beta chemokine as well as classical chemoattractant rece

50 To examine the potency of two beta-chemokines as immunomodulators, plasmid DNA encodin

51 ated protein-1 and -2, defines a subgroup of beta-chemokines based on two conserved cysteines in addi

52 monstrating that US28 is responsible for the beta-chemokine binding and induced calcium signaling in

53 CR5 NH2 terminus was important for efficient beta-chemokine binding.

54 cytolytic mechanisms include the release of beta-chemokines blocking entry of R5 HIV-1 strains.

55 nd CD8(+) T-cell subsets in tissues produced beta-chemokines both before and 21 days after SIV infect

56 Production of beta-chemokines, but not of cytokines, was increased by

57 We show that secretion of the beta-chemokines by activated lymphocytes starts before c

58 Maximal production of these beta-chemokines by activated peripheral blood cells was

59 ealed that the production of HIV-suppressive beta-chemokines by HIV antigen-stimulated PBMC was signi

60 n of antigen by T cells to the production of beta-chemokines by macrophages.

61 The synergistic induction of beta-chemokines by non-CpG-ODN was phosphorothioate (PS)

62 ombined data demonstrate that TCA3 and other beta-chemokines can modulate vascular smooth muscle cell

63 es as immunomodulators, plasmid DNA encoding beta-chemokines CCL19 and CCL21 (CCR7L) was codelivered

64 st growth factor, transforming growth factor beta, chemokine CCL2, SDF-1, and complements C3, C4, and

65 y CD4(+) and CD8(+) T cells, upregulation of beta-chemokines (CCL2 and CCL22), basic fibroblast growt

66 Therefore, drugs targeting beta-chemokines (CCL2 and CCL22), FGF-basic, HGF, or MIF

67 tion causes an increase in the expression of beta-chemokines CCL3, CCL4, and CCL5, and their receptor

68 dent on IFNalpha receptor 1 (IFNAR1) and the beta-chemokine CCL4, as IFNAR1 deficiency and neutralizi

69 treated 32D-BCR/ABL cells, we identified the beta-chemokine CCL9 as a gene regulated by BCR/ABL in a

70 monkeys had significantly higher numbers of beta-chemokine(+) CD8+ T cells than did vaccinated, prot

71 A new member of human beta-chemokine cDNA was isolated and named leukotactin-1

72 Two new members of human beta-chemokine cDNA were isolated based on structural an

73 th severe malaria have a distinct profile of beta-chemokines characterized by increased circulating l

74 Two novel human beta-chemokines, Ck beta-8 or myeloid progenitor inhibit

75 s identical to the previously isolated human beta-chemokine, CKbeta8, whereas the other is a splicing

76 kine secretion and there is no evidence that beta-chemokines contributed to the SHIV89.6-mediated con

77 of HIV-specific Th responses associated with beta-chemokines could mediate nonlytic inhibition of inf

78 Thus, even though beta-chemokines decrease HIV replication in Mphi, these

79 that: (i) CD8+ T-cell supernatants did, but beta-chemokines did not, suppress HIV replication in the

80 (iii) the CD8+ T-cell supernatants did, but beta-chemokines did not, suppress HIV-1 IIIB replication

81 RK and MEK through R2, whereas MIP-1alpha, a beta chemokine, does not activate these kinases through

82 utative amino-terminal signal sequence and a beta chemokine domain, followed by a carboxyl-terminal d

83 addition of antibodies that neutralize these beta-chemokines, either alone or in combination, only pa

84 CSF beta chemokine elevation is consistent with the macropha

85 The release of these beta-chemokines explains both the specificity for R5 HIV

86 IV infection markedly altered the pattern of beta chemokine expression elicited by tumor necrosis fac

87 ations of lymphocytes, this dysregulation of beta chemokine expression may influence the trafficking

88 us, there was a positive correlation between beta-chemokine expression and the number of beta-chemoki

89 -specific IL-2 and CTL responses, as well as beta-chemokine expression in HIV-infected and uninfected

90 mokine gene expression with higher levels of beta-chemokine expression relative to nonvaccinated anim

91 as at the level of inflammatory cytokine and beta-chemokine expression within the joint.

92 infection, monocyte brain infiltration, and beta-chemokine expression.

93 is, monocyte transendothelial migration, and beta-chemokine expression.

94 xpected four cysteines characteristic of the beta chemokine family plus two additional carboxyl-termi

95 motactic agent 4 (TCA4), a new member of the beta-chemokine family, was cloned from a mouse thymic cD

96 secreted) is a cytokine that belongs to the beta-chemokine family; it is chemoattractant for CD4+/CD

97 y CD4(+) and CD8(+) T cells, upregulation of beta-chemokines, fibroblast growth factor-basic, hepatoc

98 peripheral blood mononuclear cells secreted beta-chemokines following stimulation with HBa, and this

99 roduced similar amounts of IL-12, IL-10, and beta-chemokines, following stimulation.

100 an alternative splicing produces two active beta-chemokines from a single gene.

101 volved in the post-inflammatory clearance of beta-chemokines from cutaneous sites.

102 induce the secretion of specific alpha- and beta-chemokines from human umbilical vein endothelial ce

103 ycoproteins and by augmenting the release of beta-chemokines from NK cells.

104 beta-chemokine gene expression and release was determine

105 at least in part, from Hz-induced changes in beta-chemokine gene expression in blood mononuclear cell

106 Beta-chemokine gene expression profiles in blood mononuc

107 (NHPs) showed a better balance of alpha- and beta-chemokine gene expression with higher levels of bet

108 (beta-hematin) promote a similar pattern of beta-chemokine gene expression.

109 The synthesis of antiviral beta-chemokines has joined cytolysis as a potential mech

110 ponsible for inducing macrophages to produce beta-chemokines have not been established.

111 Two subfamilies, alpha- and beta-chemokines, have been described, based on structura

112 udies show that MCMV encodes and expresses a beta chemokine homolog with a novel predicted structure.

113 Murine cytomegalovirus carries a CC (beta) chemokine homolog gene giving rise to two related

114 r cells closely matched those of circulating beta-chemokines, illustrating that PBMCs are a primary s

115 Little is known about the participation of beta chemokines in inflammatory processes within the cen

116 In contrast, beta chemokines in plasma were either nondetectable or s

117 However, levels of beta-chemokines in AIDS patients are comparable to and c

118 s observed upon neutralization of endogenous beta-chemokines in CD8-depleted or CD4+ PBMCs from most

119 The role of beta-chemokines in HIV infection was evaluated.

120 ings is discussed in relation to the role of beta-chemokines in HIV pathogenesis.

121 We sought to clarify the role of beta-chemokines in nonprogressors and AIDS patients by e

122 e been reported to be important producers of beta-chemokines in the lymph nodes of HIV-1-infected ind

123 le of soluble effector molecules, especially beta-chemokines, in antiviral immunity is still controve

124 ith a combination of anti-CCR5 antibodies or beta-chemokines increased their fusion with X4 envelope-

125 Screening for epithelial-derived beta-chemokines indicated that IFN-gamma treatment cause

126 ostentry levels and imply the involvement of beta-chemokine-induced signaling in postentry inhibition

127 ntrast, stimulation with TCA3, but not other beta-chemokines, induces proliferation of vascular smoot

128 The kinetics of beta-chemokine induction in T cells were slow (3 to 4 da

129 infection helps to explain viral tropism and beta-chemokine inhibition of primary HIV-1 isolates.

130 A soluble factor believed to be beta-chemokine is responsible for the inhibition of M-tr

131 Although the inhibition of HIV-1 entry by beta-chemokines is well documented, their effects on pos

132 The beta chemokine known as 6-C-kine, secondary lymphoid-tis

133 tory protein-1alpha (MIP-1alpha) and RANTES, beta chemokines known to block gp120 interactions with m

134 mals also had marked elevation of alpha- and beta-chemokines known to be active on eosinophils and mo

135 charide isolated from HBa (LPS-Ba) to elicit beta-chemokines, known to bind to the human immunodefici

136 To test the hypothesis that beta-chemokine levels may be relevant to the control of

137 cytostatic agents shown here to up-regulate beta-chemokine levels, our results provide an additional

138 ability of CCR5 to signal in response to its beta-chemokine ligands is necessary or sufficient for vi

139 fined, but we have shown previously that its beta-chemokine ligands prevent HIV-1 from fusing with th

140 ns are inhibited by their natural alpha- and beta-chemokine ligands.

141 Met-Ckbeta7 is a modified form of the beta-chemokine macrophage inflammatory protein (MIP) 4 (

142 The beta-chemokine macrophage inflammatory protein (MIP)-1al

143 he T cell subsets that secrete the antiviral beta-chemokine macrophage inflammatory protein (MIP)-1be

144 is interaction was partially competed by the beta-chemokine macrophage inflammatory protein 1 beta (M

145 y structural motifs mediating binding of the beta-chemokine macrophage inflammatory protein-1alpha (M

146 ed CD8(+) T cell clone and identified as the beta-chemokine macrophage-derived chemokine (MDC).

147 esize and secrete substantial amounts of the beta-chemokines macrophage inflammatory protein (MIP)-1

148 The natural ligands of CCR5, the beta-chemokines macrophage inflammatory protein 1alpha (

149 We characterized the expression of the beta-chemokines macrophage inflammatory protein 1alpha (

150 he level of interferon-gamma (IFN-gamma) and beta-chemokines macrophage inflammatory protein-1alpha (

151 This study demonstrates that the beta-chemokines macrophage inflammatory proteins 1 alpha

152 udy compares the activity of TCA3 with other beta-chemokines (macrophage inflammatory protein (MIP)-1

153 A concomitant and marked upregulation of beta-chemokines (macrophage inhibitory proteins 1alpha a

154 The specific receptor for the beta-chemokines (macrophage-inflammatory protein (MIP)-1

155 hese factors primarily as a mixture of three beta chemokines [macrophage-derived chemokine (MDC), thy

156 with elevations in mRNA expression of three beta chemokines, macrophage-inflammatory protein 1 (MIP-

157 results of this in vitro study suggest that beta chemokines may play an important role in the traffi

158 These findings suggest that beta-chemokines may affect HIV replication when an NSI v

159 ce of endotoxin only induced the mRNA of the beta-chemokine MCP-1, and its expression was delayed com

160 t biopsies were examined for the presence of beta-chemokines (MCP-1, MIP-1alpha, MIP-1beta, and RANTE

161 The high beta-chemokine-mediated anti-HIV activity was against th

162 The sensitivity of an individual's virus to beta-chemokine-mediated inhibition correlated with the N

163 pagation of infection by failing to activate beta-chemokine-mediated inhibition of HIV-1 entry.

164 These data reveal that beta-chemokine-mediated inhibition of virus replication

165 ugh its interactions with astrocytes induces beta-chemokine-mediated monocyte migration in HAD.

166 Our results suggest that beta-chemokine-mediated resistance may be an important c

167 onocyte chemotactic protein-1 (MCP-1), a CC (beta) chemokine, mediates airway hyperreactivity in norm

168 usly described as a receptor for the related beta chemokine MIP-3beta (ELC or Exodus-3).

169 rus (HIV) biology was the discovery that the beta-chemokines MIP-1 alpha (macrophage inflammatory pro

170 In contrast, increased levels of the beta-chemokines MIP-1 alpha and -beta were seen early in

171 The beta-chemokines MIP-1alpha, MIP-1beta and RANTES inhibit

172 -alpha), but not to IFN-gamma, IFN-beta, the beta-chemokines MIP-1alpha, MIP-1beta, and RANTES, or in

173 alpha-chemokines IL-8 and SDF-1alpha and the beta-chemokines MIP-1alpha, RANTES, and MCP-1 along with

174 viously been reported, circulating levels of beta-chemokines (MIP-1alpha, MIP-1beta, and RANTES) and

175 0 production in vitro, whereas levels of the beta-chemokine monocyte chemoattractant protein-1 were s

176 ial cell line demonstrated that other murine beta-chemokines (monocyte chemotactic protein-1, macroph

177 We studied the expression of the beta-chemokines: monocyte chemoattractant protein (gene

178 experiments demonstrated that the release of beta-chemokines, most likely through FcgammaR triggering

179 own to occur in dementia and with studies of beta chemokine mRNA expression in the brain.

180 We assessed alpha and beta chemokine mRNA expression patterns and leukocyte ac

181 and SI viruses was observed at the level of beta-chemokine mRNA as well as at the level of protein e

182 unprotected monkeys had significantly higher beta-chemokine mRNA expression levels and increased numb

183 d, unprotected (n = 11) monkeys by measuring beta-chemokine mRNA levels and protein expression, the f

184 In these cells, beta-chemokine mRNA was upregulated within 30 min and pr

185 beta-Chemokine neutralization enhanced HIV infection in

186 ells remained low despite increased entry by beta-chemokine neutralization, suggesting postentry HIV

187 Finally, anti-beta-chemokine-neutralizing antibodies caused a more rap

188 However, the inhibitory effect of beta-chemokines on HIV-1 infection of macrophages has be

189 Characterization of beta-chemokines on native macaque CCR3 on eosinophils wa

190 ion, C-18 mediated inhibition did not induce beta-chemokines or cause CCR5 downmodulation, suggesting

191 ites of allergic inflammation by a number of beta-chemokines, particularly eotaxin and RANTES, the re

192 beta-chemokines play an important role in the developmen

193 that the early production of proinflammatory beta chemokines plays a major role in the severe, most o

194 A expression levels and increased numbers of beta-chemokine-positive cells than did vaccinated, prote

195 bition of HIV replication was not due to the beta-chemokines present in cocultures of cell lines with

196 The suppressive effect of beta-chemokines, principally RANTES, on certain HIV-1 is

197 n response to P. falciparum and suggest that beta-chemokines produced by maternal cells contribute to

198 The majority of beta-chemokine-producing CD8(+) T cells also produced IF

199 Macrophages are major beta-chemokine-producing cells during T-cell directed, d

200 nti-HIV effects of PTX/PTX-B were not due to beta -chemokine production or coreceptor down-modulation

201 Moreover, we asked whether higher beta chemokine production could be demonstrated with cel

202 This cellular immunotherapy can modulate beta chemokine production in patients with advanced HIV-

203 se data suggest that the effects of IL-12 on beta-chemokine production and chemokine-receptor express

204 gressors and AIDS patients by examination of beta-chemokine production and HIV-1 infection in patient

205 factors, including beta-chemokines, and that beta-chemokine production by CD4+, but not CD8+, T cells

206 summary, phenotype, cytokine secretion, and beta-chemokine production by DC from HIV+ individuals we

207 a primary source for the observed pattern of beta-chemokine production during acute malaria.

208 aluation of the effect of HIV replication on beta-chemokine production indicated that acute infection

209 gressing individuals, indicating that global beta-chemokine production may have little effect on HIV-

210 These findings suggest that constitutive beta-chemokine production may play an important role in

211 a-inducing (NSI) viruses generally increased beta-chemokine production two to eightfold, whereas with

212 imulated cell proliferation nor cytokine and beta-chemokine production was associated with the expres

213 tide-specific IL-2 responses associated with beta-chemokine production were detectable at birth in th

214 combinant CD40 ligand (CD40LT), cytokine and beta-chemokine production were similar by DC from HIV- d

215 red productive viral infection, cytokine and beta-chemokine production, and beta-chemokine receptor e

216 t also by the balance of CCR5 expression and beta-chemokine production.

217 ining or enhancing inflammatory cytokine and beta-chemokine production.

218 train ADA revealed an inverse correlation to beta-chemokine production; clones from nonprogressors we

219 Increased concentrations of the beta -chemokine RANTES were found in BAL fluid from the

220 N-Formyl-Met-Leu-Phe and the beta-chemokine RANTES (regulated on activation normal T

221 The beta-chemokine RANTES (regulated on activation, normal T

222 pression of a critical immune regulator, the beta-chemokine RANTES (regulated upon activation, normal

223 rocytes, and macrophages/microglia, that the beta-chemokines RANTES (regulated on activation, normal

224 The beta-chemokines RANTES (regulated on activation, normal

225 kines interferon-gamma and interleukin-2 and beta-chemokines RANTES (regulated upon activation, norma

226 The beta-chemokines RANTES, macrophage inflammatory protein

227 The beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta have

228 ins of HIV-1 is CC-CKR-5, a receptor for the beta-chemokines RANTES, MIP-1alpha and MIP-1beta.

229 ct likely was due to the increased levels of beta-chemokines RANTES, MIP-1alpha, and MIP-1beta becaus

230 Recent studies have demonstrated that the beta-chemokines RANTES, MIP-1alpha, and MIP-1beta suppre

231 the memory cells produced high levels of the beta-chemokines RANTES, MIP-1alpha, and MIP-1beta upon s

232 Furthermore, neither the human beta-chemokines RANTES, MIP-1alpha, MIP-1beta, and MCP-1

233 ce protein R1, plus upregulation of exodus 2 beta-chemokine, RDC1 alpha-chemokine receptor, and trans

234 in the presence of its cognate receptor, the beta chemokine receptor 2 (CCR2), produces neural activi

235 The recent identification of the CC-CKR5 beta chemokine receptor as a major cofactor for entry of

236 At the CC (beta) chemokine receptor 2 (CCR2) and CCR5 loci, combina

237 32-nucleotide deletion (delta 32) within the beta-chemokine receptor 5 (CCR5) gene has been described

238 ro produced an increase in the expression of beta-chemokine receptor 5 (CCR5).

239 The beta-chemokine receptor C-C chemokine receptor 3 (CCR3)

240 Expression of the beta-chemokine receptor CC-CKR-5 in CD4+, non-permissive

241 The beta-chemokine receptor CCR-5 is an essential co-factor

242 n this study, we evaluated the expression of beta-chemokine receptor CCR1 in the immature and adult r

243 The beta-chemokine receptor CCR3, which recognizes the ligan

244 me to inflamed tissues typically express the beta-chemokine receptor CCR5 and exhibit a Th1 cytokine

245 The beta-chemokine receptor CCR5 has been shown to modulate

246 The human beta-chemokine receptor CCR5 is an important cofactor fo

247 The beta-chemokine receptor CCR5 is required as a coreceptor

248 alpha-chemokine receptor fusin (CXCR-4) and beta-chemokine receptor CCR5 serve as entry cofactors fo

249 Surface expression of CD4 and the beta-chemokine receptor CCR5 was reduced on MDM in respo

250 hage-tropic (M-tropic) HIV-1 strains use the beta-chemokine receptor CCR5, but not CCR2b, as a cofact

251 Here, we show that the beta-chemokine receptor CKR-5 serves as a cofactor for M

252 cytokine and beta-chemokine production, and beta-chemokine receptor expression in monocyte-derived m

253 A mutant allele of the beta-chemokine receptor gene CCR5 bearing a 32-basepair

254 tor (TNF)-alpha-like receptor gene, the US28 beta-chemokine receptor gene, and the UL55 envelope glyc

255 investigate the relative contribution of the beta-chemokine receptors CCR3 and CCR5 to viral infectio

256 The beta-chemokine receptors CKR-3 and CKR-2b support HIV-1

257 fferent gp120 isolates bind to the alpha- or beta-chemokine receptors CXCR4 and CCR5, respectively.

258 An array of no less than eight beta-chemokine receptors has been identified, four of wh

259 The data suggest that beta-chemokine receptors may influence FIV infection by

260 Detection of these beta-chemokine receptors on microglia and some of their

261 d dual-tropic strains can also utilize other beta-chemokine receptors, such as CCR2b and CCR3.

262 We demonstrate here that the beta chemokines, recombinant human macrophage inflammato

263 Whereas three beta chemokines, regulated-on-activation normal T-cell e

264 TCR) following binding of antigen results in beta-chemokine release from CTLs in addition to cytolyti

265 d candidiasis is not secondary to suboptimal beta-chemokine release.

266 Neutralization of these beta-chemokines rendered memory CD4(+) cells highly sens

267 beta-chemokine expression and the number of beta-chemokine responsive cells (i.e. microglia) accumul

268 Altered patterns of circulating beta-chemokines result, at least in part, from Hz-induce

269 increased extracellular levels of anti-HIV-1 beta-chemokines resulting from transient prolongation of

270 sisting of activated CD4(+) T cells, DC, and beta-chemokine-secreting cells.

271 To determine the in vivo importance of beta-chemokine secretion and CD8+-T-cell proliferation i

272 s replication were associated with increased beta-chemokine secretion and there is no evidence that b

273 beta-Chemokines serve to attract various types of blood

274 ach, using assays that measure the effect of beta-chemokines solely on Env-mediated fusion.

275 Specific receptors for the beta-chemokine TCA3 have been identified on mouse monocy

276 h HIV-1-associated dementia and that, of the beta-chemokines tested, only MCP-1 could be detected in

277 e have isolated and characterized a human C6 beta-chemokine that is a potent agonist at CCR1 and CCR3

278 MCP-1 is a potent beta-chemokine that recruits monocytes and T cells and p

279 and macrophage inflammatory protein-1 alpha, beta-chemokines that have been suggested to have anti-HI

280 High levels of beta-chemokines, the natural ligands of the CCR5 corecep

281 and MAdCAM as well as a number of alpha- and beta-chemokines was induced or upregulated and preceded

282 The induction of CD83 and beta-chemokines was tyrosine phosphorylation dependent.

283 Beta-chemokines were expressed predominantly at the baso

284 Significant levels of beta-chemokines were produced by both CD4+ and CD8+ PBMC

285 The monocyte- and macrophage-derived beta-chemokines were sufficient to block CCR5-dependent

286 kines, but not antiinflammatory cytokines or beta-chemokines, were found to inhibit CMV expression, D

287 onocyte chemoattractant protein-1 (MCP-1), a beta chemokine which attracts cells of monocytic origin

288 This receptor is ligated by beta chemokines, which influence HIV type 1 (HIV-1) repl

289 as neutrophil chemoattractants, and the beta(beta)-chemokines, which function primarily as monocyte c

290 iased cytokine response; 3) the secretion of beta-chemokines, which are known to inhibit the use of t

291 Astrocytic release of beta-chemokines, which are relatively less selective for

292 Three beta-chemokines, which can be secreted by activated CD8+

293 Nevertheless, neutralization of beta-chemokines with specific antibodies did not abolish